GRF Stock Overview
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Grifols, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.09 |
| 52 Week High | €15.92 |
| 52 Week Low | €6.36 |
| Beta | 0.68 |
| 1 Month Change | -2.53% |
| 3 Month Change | -15.42% |
| 1 Year Change | -13.24% |
| 3 Year Change | -64.14% |
| 5 Year Change | -67.05% |
| Change since IPO | 208.04% |
Recent News & Updates
Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?
Apr 20
Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 04Recent updates
Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?
Apr 20Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 04Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive
Mar 01Does Grifols (BME:GRF) Have A Healthy Balance Sheet?
Feb 20Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price
Jan 09Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load
Nov 10Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value
Oct 20Is Grifols (BME:GRF) A Risky Investment?
Aug 03Calculating The Fair Value Of Grifols, S.A. (BME:GRF)
May 18Is Grifols (BME:GRF) Using Too Much Debt?
Apr 30Grifols (BME:GRF) Seems To Be Using A Lot Of Debt
Nov 18An Intrinsic Calculation For Grifols, S.A. (BME:GRF) Suggests It's 45% Undervalued
Oct 26Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load
Aug 18Shareholder Returns
| GRF | ES Biotechs | ES Market | |
|---|---|---|---|
| 7D | -3.1% | -4.8% | 1.8% |
| 1Y | -13.2% | -11.7% | 14.8% |
Return vs Industry: GRF underperformed the Spanish Biotechs industry which returned -11.7% over the past year.
Return vs Market: GRF underperformed the Spanish Market which returned 14.8% over the past year.
Price Volatility
| GRF volatility | |
|---|---|
| GRF Average Weekly Movement | 14.9% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in ES Market | 6.4% |
| 10% least volatile stocks in ES Market | 0.9% |
Stable Share Price: GRF's share price has been volatile over the past 3 months.
Volatility Over Time: GRF's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1909 | 23,744 | Nacho Abia | www.grifols.com |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
Grifols, S.A. Fundamentals Summary
| GRF fundamental statistics | |
|---|---|
| Market cap | €4.88b |
| Earnings (TTM) | €59.32m |
| Revenue (TTM) | €6.59b |
92.6x
P/E Ratio0.8x
P/S RatioIs GRF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRF income statement (TTM) | |
|---|---|
| Revenue | €6.59b |
| Cost of Revenue | €4.10b |
| Gross Profit | €2.49b |
| Other Expenses | €2.44b |
| Earnings | €59.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | 0.087 |
| Gross Margin | 37.84% |
| Net Profit Margin | 0.90% |
| Debt/Equity Ratio | 119.6% |
How did GRF perform over the long term?
See historical performance and comparison